[96a5a0]: / output / allTrials / identified / NCT06162572_identified.json

Download this file

629 lines (629 with data), 27.0 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
{
"info": {
"nct_id": "NCT06162572",
"official_title": "A Phase 1b/2, Multicenter, Open-label Platform Study of Select Immunotherapy Combinations in Adult Participants With Previously Untreated Advanced Non-small Cell Lung Cancer (NSCLC) With High PD-L1 Expression",
"inclusion_criteria": "* Adult patient aged ≥ 18 years\n* Written informed consent\n* Histologically (squamous or non-squamous) or cytologically documented locally advanced NSCLC not eligible for surgical resection and/or definitive chemoradiation, or metastatic NSCLC\n* No prior systemic treatment for locally advanced or metastatic NSCLC\n* High tumor cell PD-L1 expression [Tumor Proportion Score (TPS) ≥50%] based on documented status as determined by an approved test\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n* Measurable disease as determined by RECIST v1.1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Tumors harboring driver mutations/genetic aberrations for which targeted therapies are approved as frontline treatment (e.g. EGFR mutation, ALK fusion oncogene, ROS1 aberrations)\n* Prior immune checkpoint inhibitor therapy\n* Active brain metastases\n* Participants with active and uncontrolled hepatitis B virus (HBV) or hepatitis C virus (HCV) infection\n* Uncontrolled HIV infection. Participants with HIV who have controlled infection (undetectable viral load and CD4 count above 350 either spontaneously or on a stable antiviral regimen) are allowed to enroll\n* Active, known or suspected autoimmune disease or immune deficiency\n* History of hypersensitivity reactions to any ingredient of the investigational medicinal product (IMP) and other monoclonal antibody (mAbs) and/or their excipients\n* History of interstitial lung disease, idiopathic pulmonary fibrosis, drug-induced pneumonitis, idiopathic pneumonitis or active pneumonitis ≥ grade 2\n* History of inflammatory bowel disease or colitis ≥ grade 2\n* Systemic chronic steroid therapy (>10mg/d prednisone or equivalent)\n* Active infection, including infection requiring systemic antibiotic therapy\n* Pregnant or breast-feeding (lactating) women\n* Participants with a history of allogeneic organ transplantation (e.g., stem cell or solid organ transplant)\n* Any medical condition that would in the investigator's judgement prevent the participant's participation in the clinical study",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Adult patient aged ≥ 18 years",
"criterions": [
{
"exact_snippets": "Adult patient aged ≥ 18 years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum age",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
]
}
]
},
{
"line": "* Written informed consent",
"criterions": [
{
"exact_snippets": "Written informed consent",
"criterion": "informed consent",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Histologically (squamous or non-squamous) or cytologically documented locally advanced NSCLC not eligible for surgical resection and/or definitive chemoradiation, or metastatic NSCLC",
"criterions": [
{
"exact_snippets": "Histologically (squamous or non-squamous) or cytologically documented",
"criterion": "NSCLC documentation",
"requirements": [
{
"requirement_type": "method",
"expected_value": [
"histologically",
"cytologically"
]
}
]
},
{
"exact_snippets": "locally advanced NSCLC",
"criterion": "NSCLC stage",
"requirements": [
{
"requirement_type": "stage",
"expected_value": "locally advanced"
}
]
},
{
"exact_snippets": "not eligible for surgical resection and/or definitive chemoradiation",
"criterion": "treatment eligibility",
"requirements": [
{
"requirement_type": "eligibility",
"expected_value": "not eligible for surgical resection and/or definitive chemoradiation"
}
]
},
{
"exact_snippets": "metastatic NSCLC",
"criterion": "NSCLC stage",
"requirements": [
{
"requirement_type": "stage",
"expected_value": "metastatic"
}
]
}
]
},
{
"line": "* No prior systemic treatment for locally advanced or metastatic NSCLC",
"criterions": [
{
"exact_snippets": "No prior systemic treatment",
"criterion": "prior systemic treatment",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "locally advanced or metastatic NSCLC",
"criterion": "NSCLC stage",
"requirements": [
{
"requirement_type": "stage",
"expected_value": [
"locally advanced",
"metastatic"
]
}
]
}
]
},
{
"line": "* High tumor cell PD-L1 expression [Tumor Proportion Score (TPS) ≥50%] based on documented status as determined by an approved test",
"criterions": [
{
"exact_snippets": "High tumor cell PD-L1 expression ... Tumor Proportion Score (TPS) ≥50% ... as determined by an approved test",
"criterion": "tumor cell PD-L1 expression",
"requirements": [
{
"requirement_type": "expression level",
"expected_value": {
"operator": ">=",
"value": 50,
"unit": "%"
}
},
{
"requirement_type": "test approval",
"expected_value": true
}
]
}
]
},
{
"line": "* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1",
"criterions": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1",
"criterion": "ECOG Performance Status",
"requirements": [
{
"requirement_type": "value",
"expected_value": [
"0",
"1"
]
}
]
}
]
},
{
"line": "* Measurable disease as determined by RECIST v1.1",
"criterions": [
{
"exact_snippets": "Measurable disease as determined by RECIST v1.1",
"criterion": "measurable disease",
"requirements": [
{
"requirement_type": "determination method",
"expected_value": "RECIST v1.1"
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Tumors harboring driver mutations/genetic aberrations for which targeted therapies are approved as frontline treatment (e.g. EGFR mutation, ALK fusion oncogene, ROS1 aberrations)",
"criterions": [
{
"exact_snippets": "Tumors harboring driver mutations/genetic aberrations ... EGFR mutation",
"criterion": "EGFR mutation",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Tumors harboring driver mutations/genetic aberrations ... ALK fusion oncogene",
"criterion": "ALK fusion oncogene",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Tumors harboring driver mutations/genetic aberrations ... ROS1 aberrations",
"criterion": "ROS1 aberrations",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Prior immune checkpoint inhibitor therapy",
"criterions": [
{
"exact_snippets": "Prior immune checkpoint inhibitor therapy",
"criterion": "immune checkpoint inhibitor therapy",
"requirements": [
{
"requirement_type": "prior treatment",
"expected_value": true
}
]
}
]
},
{
"line": "* Active brain metastases",
"criterions": [
{
"exact_snippets": "Active brain metastases",
"criterion": "brain metastases",
"requirements": [
{
"requirement_type": "activity",
"expected_value": "active"
}
]
}
]
},
{
"line": "* Participants with active and uncontrolled hepatitis B virus (HBV) or hepatitis C virus (HCV) infection",
"criterions": [
{
"exact_snippets": "active and uncontrolled hepatitis B virus (HBV)",
"criterion": "hepatitis B virus (HBV) infection",
"requirements": [
{
"requirement_type": "status",
"expected_value": "active"
},
{
"requirement_type": "control",
"expected_value": "uncontrolled"
}
]
},
{
"exact_snippets": "active and uncontrolled ... hepatitis C virus (HCV) infection",
"criterion": "hepatitis C virus (HCV) infection",
"requirements": [
{
"requirement_type": "status",
"expected_value": "active"
},
{
"requirement_type": "control",
"expected_value": "uncontrolled"
}
]
}
]
},
{
"line": "* Uncontrolled HIV infection. Participants with HIV who have controlled infection (undetectable viral load and CD4 count above 350 either spontaneously or on a stable antiviral regimen) are allowed to enroll",
"criterions": [
{
"exact_snippets": "Uncontrolled HIV infection",
"criterion": "HIV infection",
"requirements": [
{
"requirement_type": "control status",
"expected_value": "uncontrolled"
}
]
},
{
"exact_snippets": "HIV who have controlled infection (undetectable viral load",
"criterion": "HIV infection",
"requirements": [
{
"requirement_type": "control status",
"expected_value": "controlled"
}
]
},
{
"exact_snippets": "undetectable viral load",
"criterion": "viral load",
"requirements": [
{
"requirement_type": "detectability",
"expected_value": "undetectable"
}
]
},
{
"exact_snippets": "CD4 count above 350",
"criterion": "CD4 count",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">",
"value": 350,
"unit": "N/A"
}
}
]
},
{
"exact_snippets": "stable antiviral regimen",
"criterion": "antiviral regimen",
"requirements": [
{
"requirement_type": "stability",
"expected_value": "stable"
}
]
}
]
},
{
"line": "* Active, known or suspected autoimmune disease or immune deficiency",
"criterions": [
{
"exact_snippets": "Active, known or suspected autoimmune disease",
"criterion": "autoimmune disease",
"requirements": [
{
"requirement_type": "status",
"expected_value": [
"active",
"known",
"suspected"
]
}
]
},
{
"exact_snippets": "immune deficiency",
"criterion": "immune deficiency",
"requirements": [
{
"requirement_type": "status",
"expected_value": [
"active",
"known",
"suspected"
]
}
]
}
]
},
{
"line": "* History of hypersensitivity reactions to any ingredient of the investigational medicinal product (IMP) and other monoclonal antibody (mAbs) and/or their excipients",
"criterions": [
{
"exact_snippets": "History of hypersensitivity reactions to any ingredient of the investigational medicinal product (IMP)",
"criterion": "hypersensitivity reactions to IMP ingredients",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "hypersensitivity reactions to ... other monoclonal antibody (mAbs)",
"criterion": "hypersensitivity reactions to monoclonal antibodies",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "hypersensitivity reactions to ... their excipients",
"criterion": "hypersensitivity reactions to excipients",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
}
]
},
{
"line": "* History of interstitial lung disease, idiopathic pulmonary fibrosis, drug-induced pneumonitis, idiopathic pneumonitis or active pneumonitis ≥ grade 2",
"criterions": [
{
"exact_snippets": "History of interstitial lung disease",
"criterion": "interstitial lung disease",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "idiopathic pulmonary fibrosis",
"criterion": "idiopathic pulmonary fibrosis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "drug-induced pneumonitis",
"criterion": "drug-induced pneumonitis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "idiopathic pneumonitis",
"criterion": "idiopathic pneumonitis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "active pneumonitis ≥ grade 2",
"criterion": "active pneumonitis",
"requirements": [
{
"requirement_type": "severity",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "grade"
}
}
]
}
]
},
{
"line": "* History of inflammatory bowel disease or colitis ≥ grade 2",
"criterions": [
{
"exact_snippets": "History of inflammatory bowel disease",
"criterion": "inflammatory bowel disease",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "colitis ≥ grade 2",
"criterion": "colitis",
"requirements": [
{
"requirement_type": "severity",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "grade"
}
}
]
}
]
},
{
"line": "* Systemic chronic steroid therapy (>10mg/d prednisone or equivalent)",
"criterions": [
{
"exact_snippets": "Systemic chronic steroid therapy (>10mg/d prednisone or equivalent)",
"criterion": "systemic chronic steroid therapy",
"requirements": [
{
"requirement_type": "dosage",
"expected_value": {
"operator": ">",
"value": 10,
"unit": "mg/d prednisone or equivalent"
}
}
]
}
]
},
{
"line": "* Active infection, including infection requiring systemic antibiotic therapy",
"criterions": [
{
"exact_snippets": "Active infection",
"criterion": "active infection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "infection requiring systemic antibiotic therapy",
"criterion": "infection requiring systemic antibiotic therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Pregnant or breast-feeding (lactating) women",
"criterions": [
{
"exact_snippets": "Pregnant",
"criterion": "pregnancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "breast-feeding (lactating)",
"criterion": "breastfeeding",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Participants with a history of allogeneic organ transplantation (e.g., stem cell or solid organ transplant)",
"criterions": [
{
"exact_snippets": "history of allogeneic organ transplantation",
"criterion": "allogeneic organ transplantation",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
}
]
},
{
"line": "* Any medical condition that would in the investigator's judgement prevent the participant's participation in the clinical study",
"criterions": [
{
"exact_snippets": "Any medical condition that would in the investigator's judgement prevent the participant's participation",
"criterion": "medical condition",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "prevents participation"
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}